Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...
Kennedy Jr. has been a vocal critic of the pharma industry. He’s said it’s corrupted U.S. health agencies and has attacked, ...
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by ...
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research Report). The company’s shares closed yesterday at $56.80. Don't ...
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
GlobalData on MSN11h
Novartis strengthens radiopharma leadership with Ratio Therapeutics dealNovartis has teamed up with Ratio Therapeutics in a $745m licensing and collaboration agreement to advance ...
In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report), with a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback